



STUDY PROTOCOL

REVISED SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART) [version 2; peer review: 2 approved, 1 approved with reservations]

Kathryn Maitland ^{1,2}, Mainga Hamaluba ², Nchafatso Obonyo ², Emmanuel Oguda², Christabel Mogoka², Thomas N. Williams ^{1,2}, Mike Chaponda^{3,4}, Sam Miti^{3,4}, Luc Kambale Kamavu^{4,5}, Jonathan Jonathan Gwasupika ^{3,4}, Roisin Connon ⁶, Diana M. Gibb ⁶, Arjen Dondorp ⁷, Nick Day ⁷, Nick White ⁷, A. Sarah Walker⁶, Elizabeth C. George⁶, Severe Malaria in African Children A Research and Trials (SMAART) consortium

¹Department of Infectious Disease and Institute of Global Health and Innovation, Imperial College London, London, England, UK
²Clinical Research, 1. KEMRI-Wellcome Trust Research Programme, Kilifi, Kilifi, Po Box 230, Kenya
³Tropical Diseases Research Centre, Ndola, P.O Box 71769, Zambia
⁴St. Pauls' Mission Hospital, Nchelenge, Luapula Province, Zambia
⁵Arthur Davison Children's Hospital, Ndola, P.O. Box 240227, Zambia
⁶Medical Research Council Clinical Trials, University College London, London, England, WC1V 6LJ, UK
⁷Clinical Trials, Mahidol Oxford Tropical Medicine Research Unit, Bangkok, 10400, Thailand

v2 First published: 20 Oct 2023, 8:484
<https://doi.org/10.12688/wellcomeopenres.20111.1>
Latest published: 12 Aug 2024, 8:484
<https://doi.org/10.12688/wellcomeopenres.20111.2>

Abstract

Background

Even on the best antimalarial treatments (injectable artesunate) African children with severe malaria have poor outcomes with most deaths occurring early in the course of hospital admission (<24hours). Lactic acidosis, largely due to impairment of the microcirculatory flow due to parasite sequestration, is a main risk factor for poor outcome. There are no adjuvant treatments for severe malaria that target this complication. Sevuparin, a heparin-like drug, binds to *Plasmodium falciparum* erythrocyte membrane protein blocking merozoite invasion, preventing cytoadherence and transiently de-sequestering infected erythrocytes. Leading to improved microcirculatory flow by

Open Peer Review

Approval Status   

	1	2	3
version 2 (revision) 12 Aug 2024		 view	
version 1 20 Oct 2023	 view	 view	 view

1. Mei Li, National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, China
2. Bruno Mmbando , Muhimbili University of

reversing/preventing parasite sequestration. If given early during admission this could result in improvements in outcomes. Sevuparin has been shown to be safe and well tolerated in adults with only some mild transient effects on activated partial thromboplastin time (APTT) were reported, without clinical consequences.

Methods

A Phase I trial designed to provide data on safety, dosing, feasibility of sevuparin as an adjuvant therapy in Kenya and Zambian children with severe malaria complicated by lactic acidosis ($> 2\text{mmol/l}$). Three intravenous doses will be given at admission (0 hours), 8 and 16 hours. APPT will be measured 1 hour after each dose (to assess maximum toxicity). Studying 20 children will allow sufficient data on safety to be generated across a range of doses to identify the maximum tolerated dose (MTD) using the Continual Reassessment Method, which adapts or informs subsequent doses for each child based on the data from previously enrolled children. The MTD will be identified based on the dose-toxicity model updated by each previous patient's APTT results using standard methods.

Conclusions

The results of the Phase I trial will identify the final dose to be tested in a Phase II trial in terms of both efficacy and safety outcomes.

Registration

PACTR number: 202007890194806 (date 20/07/2020) ISRCTN32271864 (date 28/07/2021)

Keywords

severe malaria, adjunctive therapy, children, Africa, clinical trial, heparin-like molecule

Health and Allied Sciences, Dar es Salaam, Tanzania

National Institute for Medical Research, Tanga, Tanzania

Kampala International University - Dar es Salaam College, Dar es Salaam, Tanzania

3. **Joerg J. Moehrle** , Medicines for Malaria Venture, Geneva, Switzerland

Any reports and responses or comments on the article can be found at the end of the article.



This article is included in the [KEMRI | Wellcome Trust gateway](#).

Corresponding author: Kathryn Maitland (k.maitland@imperial.ac.uk)

Author roles: **Maitland K:** Conceptualization, Funding Acquisition, Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing; **Hamaluba M:** Conceptualization, Investigation, Project Administration, Writing – Review & Editing; **Obonyo N:** Investigation, Methodology, Writing – Review & Editing; **Oguda E:** Project Administration, Supervision, Validation; **Mogoka C:** Data Curation, Project Administration, Software, Validation; **Williams TN:** Conceptualization, Investigation, Resources, Writing – Review & Editing; **Chaponda M:** Investigation, Project Administration, Supervision, Writing – Review & Editing; **Miti S:** Investigation, Project Administration, Supervision; **Kamavu LK:** Data Curation, Investigation, Supervision; **Jonathan Gwasupika J:** Investigation, Project Administration; **Connors R:** Formal Analysis, Methodology, Validation, Visualization; **Gibb DM:** Conceptualization, Funding Acquisition, Methodology, Writing – Review & Editing; **Dondorp A:** Conceptualization, Funding Acquisition, Methodology, Validation, Writing – Review & Editing; **Day N:** Conceptualization, Funding Acquisition, Methodology, Writing – Review & Editing; **White N** : Conceptualization, Funding Acquisition, Methodology, Writing – Review & Editing; **Walker AS:** Conceptualization, Formal Analysis, Funding Acquisition, Methodology, Validation, Visualization, Writing – Review & Editing; **George EC:** Conceptualization, Formal Analysis, Methodology, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing;

Competing interests: No competing interests were disclosed.

Grant information: The trial was supported by a Wellcome Collaborative Grant in Science [209265, <https://doi.org/10.35802/209265>]. MODUS Therapeutics AB, Olof Palmes väg 29 IV, SE-111 22, Stockholm, Sweden provided Sevuparin for the trial. *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

Copyright: © 2024 Maitland K *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Maitland K, Hamaluba M, Obonyo N *et al.* **SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART) [version 2; peer review: 2 approved, 1 approved with reservations]** Wellcome Open Research 2024, 8:484 <https://doi.org/10.12688/wellcomeopenres.20111.2>

First published: 20 Oct 2023, 8:484 <https://doi.org/10.12688/wellcomeopenres.20111.1>

REVISED Amendments from Version 1

We have edited the text and table to correct some of the omissions (admission FBC missing from the table, additional abbreviations) and corrected some of typos and misleading sentences. No major changes have been made to the protocol,

In addition we have added an additional author and corrected some of the hospital names and author affiliations in Zambia

All authors have signed a statement to agree to the additional author.

Any further responses from the reviewers can be found at the end of the article

Abbreviations

ACT	Artemisinin combination therapy
AE	Adverse event
APTT	Activated partial thromboplastin time
AT	Antithrombin
BCS	Blantyre Coma Scale
CI	Confidence interval
CM	Cerebral Malaria
CRF	Case Record Form
CRM	Continuous Reassessment Method
CTC	Common Toxicity Criteria
DIC	Disseminated intravascular coagulation
DLT	Dose limiting toxicity
DMC	Data Monitoring Committee
ECG	Electrocardiogram
ED50	Median effective dose (effective dose for 50% of people receiving the drug)
FBC	Full Blood Count
GMP	Good Manufacturing Practice
HDU	High Dependency Unit
HRP2	<i>P. falciparum</i> Histidine Rich Protein 2
IV	Intravenous
KCH	Kilifi County Hospital
KEMRI	Kenya Medical Research Institute
KWTRP	Kilifi Wellcome Trust Research Programme
ICREC	Imperial College Research Ethics Committee
MRC CTU	Medical Research Council Clinical Trials Unit
MTD	Maximal tolerated dose
OR	Odds ratio
PI	Principal Investigator
PK	Pharmacokinetic

PKPD	Pharmacokinetic-pharmacodynamic
POC	Point of Care
RDT	Rapid diagnostic test
SAE	Serious adverse event
SDF	Side stream-dark field
SERU	Scientific and Ethics Review Unit
SMAART	Severe Malaria in African children: A Research and Trials consortium
SOP	Standard Operating Procedures
TAT	Thrombin-AT III
TF	Tissue factor
TM	Thrombomodulin
ULN	Upper limit of normal

Introduction

Over the last decade there has been an unprecedented rise in funding for malaria control activities, including the scale-up in long-lasting insecticidal bed nets and introduction and access to effective artemisinin-combination treatments (ACT). This has resulted in the disease retreating from large parts of the globe, yet malaria remains stubbornly unyielding in sub-Saharan Africa and in some parts of Asia¹. In some African countries, the pattern of transmission has not changed appreciably, despite implementation of early treatment and control strategies and they continue to contribute most to the global disease burden². Many of the African countries most afflicted by malaria are amongst the poorest on the continent with weak health services infrastructure. Severe malaria remains a major public health problem in Africa and a chief factor in child mortality; particularly in countries experiencing high transmission. In 2016 it was estimated that there were over 445,000 deaths from malaria with the vast majority of these deaths in African children^{3,4}. Whilst the AQUAMAT trial has provided definitive evidence for optimal antimalarial treatment in severe malaria⁵, progress on improving outcome through supportive or adjunctive treatments has been very slow^{6,7}.

Treatment of severe malaria

The multi-centre AQUAMAT trial conducted in 11 centres in 9 countries in Africa compared quinine and artesunate in 5425 children hospitalised with severe malaria. The primary endpoint, in-hospital mortality, in the intention to treat analysis occurred in 297/2713 (10.9%) children receiving quinine treatment compared to 230/2712 (8.5%) children receiving artesunate - translating to a relative reduction in mortality of 22.5% (95% CI 8.1-36.9) with artesunate ($p=0.002$)⁵. However, outside the context of a clinical trial, overall in-patient mortality for severe malaria remains unacceptably high (~10%), and unlikely to improve without wider implementation of pre-referral artemisinin⁸ and better supportive treatments^{6,9}. As demonstrated in [Table 1](#) below, case fatalities in AQUAMAT were even higher within large subgroups of patients presenting with one or more of the 3 key prognostic markers (coma, acidosis, or a high blood urea nitrogen)¹⁰. Evidence guiding best management of these and other complications is lacking.

Table 1. High priority risk factors for severe malaria and recent trials.

Admission feature or complication	Frequency	In-hospital Mortality* (Artesunate-arm) ⁵	
Coma	32–35%	18%	
Metabolic acidosis (base excess<-8 or lactate>5mmol/L)	43–44%	15%	
Renal impairment (Urea/BUN > 20 mmol/L)	24%	22%	
Hypoglycaemia (blood glucose <3 mmol/L)	10%	15% ¹¹	
Convulsions	30–32%	14%	
Invasive bacterial co-infection	5.5%	24% (Meta-analysis) ¹²	
Blackwater Fever (region specific)	14–21%	Day-28 mortality 12% ¹³	
Recent or ongoing trials	Frequency	Mortality	Trial: results expected
Shock (mortality = no-bolus arm)	12%	8.5%	FEAST: published ¹⁴
Severe anaemia	29–30%	1%	TRACT: published ^{15,16}
Hypoxaemia (<90%)	15%–17%	2–13%	COAST: published ¹⁷

* Data are from AQUAMAT trial unless otherwise stated

To date none of 33 clinical trials of adjunctive (supportive) treatments conducted globally since a seminal severe malaria trial in 1980 have shown benefit⁶. Over 60% of these trials involved children and 15 were specifically directed to the sub-group with cerebral malaria. The majority were single-centre Phase I or II trials involving few participants, and a reasonable number were stopped prematurely because they showed harm.

Severe Malaria in African children A Research and Trials Consortium (SMAART)

Severe Malaria In African Children: A Research and Trials Consortium (SMAART) was funded in 2018 by a collaboration award in science from the Wellcome Trust. The major objective of the consortium was to identify which interventions could optimise the whole treatment pathway for children with severe malaria to survival 6-months post-discharge, and hence achieve a step-change in improving their outcomes in the current era. The SMAART consortium reviewed the high priority areas of research and key targets for intervention. One high risk group identified by the group was children presenting with acidosis (increased base excess); in this sub-group mortality remained at 15%, and acidosis was one of the three key factors predicting poor outcome¹⁰. In order to identify supportive therapies which could target acidosis, the following section summarises the current understanding of the pathophysiology of severe malaria and likely aetiology of 'malaria' acidosis.

Pathophysiology of severe malaria and metabolic acidosis

During the course of infection, ring stage parasitaemia or infected erythrocytes in children with *P. falciparum* is amplified. Unlike other malaria species, *Plasmodium falciparum* has the unique ability to cause cytoadherence, a phenomenon

called sequestration, of late stage parasitised infected erythrocytes in the deep vascular beds¹⁸. The pathophysiological process is mediated by excessive sequestration of *P. falciparum* infected erythrocytes¹⁹, rosetting²⁰ and decreased deformability of non-parasitised red cells²¹. Whilst this can occur during a non-severe infection, autopsy studies have shown that there is intense sequestration of parasitized erythrocytes in vital organs in children who have died from malaria (i.e., had severe malaria), but sequestration varies between organs, and even varies even within an organ, with some vessels completely blocked while other proximate vessels remain patent^{21,22}. Whether sequestration causes mechanical obstruction and impaired tissue perfusion or is damaging in other ways (active parasite metabolism, release of toxins, cytokine induction)²³ is not known.

One marker associated with poor outcome is a raised lactate, which is generally considered to be directly linked to the degree of impaired perfusion²⁴. Evidence to support this include the fact that improvements in lactate concentration over the first 24 hours of admission were strongly prognostic for survival in adults with severe malaria²⁵. Moreover, faster clearance of plasma lactate was predictive of the treatment effect on mortality of artemether compared to quinine²⁶. Artemether results in a rapid killing of ring stage parasites, preventing their further maturation and sequestration in the microcirculation and this is thought to be a main contributor to the improvement in case fatality. In the fluid expansion as a supportive therapy (FEAST) trial, which included a large number of children with severe malaria, a sub-analysis showed that severe lactataemia (>5 mmol/L) was strongly associated with mortality (Odds Ratio (OR) 6.96; 95% CI 3.52, 13.76, p<0.001) and that failure to clear lactate at 8 hours was strongly associated with death at 72h (OR 4.62; 95% CI 2.7, 8.0; p < 0.001)²⁷.

Adjuvant or supporting treatments aiming at improving the microcirculation

The demonstration in autopsy studies of microvascular obstruction by a heavy parasite burden²⁸ and that an overall measure of parasite biomass (*Plasmodium falciparum* histidine-rich protein2 (pfHRP2), a protein released on sequestration by infected erythrocytes), correlates with worse outcomes²⁹ suggest that adjuvant therapies which can reverse sequestration and reduce overall biomass (by preventing merozoite invasion) early in the course of the disease may lead to substantial improvements when the risk of fatal outcome is highest. Moreover, the time of development of a merozoite into an adhesive infected erythrocyte that sequesters and blocks the micro-vasculature is ~18–20 hours which is the same time period (first day of hospitalization) when the majority of paediatric deaths from severe malaria in Africa occur.

In studies conducted in Indonesia, it was hypothesized that heparin could inhibit *P. falciparum* sequestration and merozoite invasion since heparin binds to heparan sulphate binding structure of *Plasmodium falciparum* erythrocyte membrane protein 1 (PfEMP1), the Duffy-binding like domain 1 α (DBL1 α), known as a vital contributor to sequestration of infected erythrocytes^{30,31}. Clinical trials showed that heparin, as an adjunctive therapy to antimalarial drugs, had variable results, with some showing reduced mortality in children with severe *P. falciparum* malaria^{32,33}, others showing no clinical improvements when given as a low dose³⁴ and others demonstrating potentially severe effects on coagulation in simian studies in *P. knowlesi* malaria at the same dosage as those showing benefit in children with severe malaria^{35,36}. As a result, heparin was not subsequently adopted into clinical practice owing to the substantial concern over haemostatic side effects. Subsequent investigation has shown that the inhibitory effect of heparin on *P. falciparum* sequestration and merozoite invasion (which also is mediated through the heparan sulphate binding site of PfEMP) is independent of its anti-coagulant activity^{37,38}. The next step was to develop a heparin compound that was devoid of its therapeutic limiting effects on coagulation.

SEVUPARIN

The drug sevuparin was developed from heparin because it was necessary to conserve a heparan sulfate binding activity that was as similar as possible to that of heparin. Thus, the rationale was that sevuparin would act as a decoy receptor during malaria infection³⁹. Sevuparin, akin to other heparins, is a poly-disperse chemical, encompassing a range of polysaccharide chain lengths with molecular weights of 3.6–9.6 kDa. Sevuparin is negatively charged and derived from heparin through chemical depolymerization. In sevuparin, the specific pentasaccharide involved in high-affinity binding to antithrombin III has been deleted. Thus, since sevuparin has no specific binding sequence for antithrombin (AT) which is the main contributor to prolonged coagulation, it has no direct effect on factor Xa or on thrombin, and its effect on activated partial thromboplastin time (APTT) is markedly reduced compared to that of standard dose heparin⁴⁰. For example, for it to have the same effect (ED50) on APTT prolongation (measured as ED50), sevuparin would need to be given in

doses five times higher compared to low molecular weight heparin and 35 times higher compared to full length heparin.

Like heparin, sevuparin binds to the heparin sulphate binding structure of *Plasmodium falciparum* erythrocyte membrane protein 1 (PfEMP1), which is the key receptor for sequestration of infected erythrocytes^{40,41}. Preclinical investigations have demonstrated that sevuparin blocks *P. falciparum* merozoite invasion into fresh erythrocytes *in vitro*, and both disrupts and blocks the binding of infected erythrocytes to uninfected erythrocytes (rosetting) and binding to vascular endothelial cells (also known as cytoadherence) *in vitro*. *In vivo* studies also demonstrated that sevuparin led to de-sequestering of schizonts both rats and in non-human primate preclinical studies^{32–34} and to disruption of rosetting in a dose-dependent manner⁴¹.

Phase I studies in healthy volunteers and a clinical study of adults with sevuparin (including a dose escalation trial) have been conducted in patients with mild *P. falciparum* malaria in which it was hypothesised that sevuparin would act as a decoy receptor during malaria infection to block merozoite invasion as an adjunctive therapeutic approach to preclude the early expansion of an infection and reduce the sequestered biomass⁴².

In the Phase I dose escalation trial, sevuparin was found to be safe and well-tolerated with minimal effects on APTT at doses of 1.5 mg/kg and 3mg/kg every six hours but a dose of 6.0 mg/kg led to higher APTT values. The Data Monitoring Committee (DMC) therefore recommended that the study should continue to the Phase II with a dose of 3.0 mg/kg sevuparin every 6h, given the potentially increased risk of adverse events at higher doses⁴².

In the Phase II trial, sevuparin was administered as an intravenous infusion over 5 minutes in addition to standard care i.e., a fixed dose combination of 1000 mg atovaquone and 400 mg proguanil once daily for three days, in subjects with uncomplicated *P. falciparum* malaria (experimental arm), as compared to atovaquone/proguanil treatment alone (control). There were minimal and non-clinically relevant changes in anti-Xa- and prothrombin-times, and the international normalized ratios associated to the sevuparin dose. Increases in APTT were dose-dependent and appeared to follow the time-concentration curve for each sevuparin infusion. The 6-hour interval between the infusions allowed for nearly full reversibility of APTT levels after each dose, and no accumulative effects were seen over the course of the 12 consecutive infusions. Thrombocytopenia occurred in one subject but was noted to be present before the initiation of sevuparin treatment. There was no incident of bleeding in any of the participants nor were there any other serious adverse events or adverse events⁴².

Sevuparin was therefore judged to be safe and well tolerated in adults with mild malaria and was found to be safe with minimal side effects in other clinical trials⁴³. It led to a reduction in numbers of ring-stage infected erythrocytes after a single

sevuparin infusion and resulted in a transient appearance of mature parasite infected erythrocytes (schizonts appearing in the circulation, indicating these had been released after desequstration). These both occurred within one hour after the first sevuparin injection. Thus, these studies indicate that a novel new drug candidate for adjunctive treatment of severe malaria had been identified that blocks merozoite invasion and transiently de-sequesters infected erythrocytes in humans with uncomplicated *P. falciparum* malaria.

What is known about coagulation in severe malaria?

Endothelial injury, whether due to trauma, inflammation or infection causes activation of three main pro-coagulant pathways: the coagulation cascade, platelet reactions and vasoconstriction. In severe *P. falciparum* malaria, adhesion molecule upregulation has been demonstrated^{44,45} and thrombomodulin levels (TM) have been reported to be high^{45,46} suggesting that any coagulation activation seen might be due to endothelial dysfunction. Few detailed studies exist of coagulation abnormalities in severe malaria; frank disseminated intravascular coagulation (DIC) is rare despite thrombocytopenia being common^{47–49}. Early studies of the mechanisms involved in the activation of the coagulation cascade in severe *falciparum* malaria in Thai adults, many of whom had multiple vital organ dysfunction, suggested activation of the intrinsic pathway of the clotting cascade and complement system including reduction in the concentration of plasma antithrombin III (AT III) concentrations, elevation in thrombin-AT III (TAT) complexes^{50,51}, and reductions in factor XII and pre-kallikrein activities. Protein-C activity was also shown to be reduced⁵¹. Subsequent studies have also shown that *P. falciparum* malaria is associated with procoagulant activity but not with clinical evidence of thromboembolism. Plasma levels of TM have been used to assess the participation of the vascular endothelium in human *falciparum* malaria. Studies in adults have shown that elevated plasma levels of TM correlate directly with the levels of parasitaemia, TNF alpha, elastase and TAT^{46,52}; and that the low plasma levels of Protein-C and protein-C inhibitor-1 and increased TAT concentrations present in almost all patients correlated with severity and parasitaemia. Together these data suggest that there is endothelial activation and a shift towards a pro-coagulant state in *P. falciparum* malaria, both of which can be reversed after anti-malarial treatment⁵².

Paediatric studies of coagulation in severe malaria

Studies of coagulation in African children with severe malaria are relatively few but clinical evidence of DIC is rare⁵³. In paediatric cerebral malaria (CM), autopsy studies have shown that fibrin degradation products are raised, indicating a pro-coagulant state⁵⁴. These studies also showed a consistent staining for tissue factor (TF) in the endothelial cells and TF was also shown to be upregulated in the brain post-mortem studies in paediatric CM⁵⁵. However, the latter study also showed that TF was also found in post-mortem samples from parasitaemic children whose underlying illness was non-malarial⁵⁵. Moreover, when comparing functional coagulation assays in African children with CM to children with mild malaria, no marked differences were found⁵⁶.

A more recent and comprehensive case-control study of coagulation compared a range of indices in children with true cerebral malaria (defined by a malarial retinopathy) compared with children with other forms of severe malaria, mild malaria and healthy controls. Compared to healthy controls (n=19), TAT, a sensitive marker of thrombin generation, was increased in children with retinopathy-positive CM (n=66) ($P<0.001$) and levels were greater than those in children with uncomplicated malaria (n=30) ($P<0.01$). In the retinopathy-positive CM group, TAT levels were higher in 16 fatalities than in those children who survived. Prothrombin times were mildly and similarly prolonged in both CM children and children with uncomplicated malaria compared to healthy controls⁵⁷. APTT levels were similar to the controls in all malaria groups, indicating activation of coagulation through TF activation rather than increased factor XII⁵¹.

Protocol

Trial registration

PACTR number: 202007890194806 (registered on 20/07/2020)

ISRCTN32271864 (was registered on 28/07/2021 and updated on 18/08/2023)

Protocol Version 2.1 Date 28th February 2023

This protocol follows the SPIRIT guidelines⁵⁸.

Justification for the study

The poor outcomes in children with severe malaria complicated by lactic acidosis indicates that adjunctive therapies directed at the pathophysiology underpinning acidosis may be beneficial. A novel new drug candidate, sevuparin, has been identified that can block merozoite invasion, prevent cytoadherence and transiently de-sequesters infected erythrocytes – the main causes of microvascular blood flow impairment (and likely aetiology of acidosis). If given, in addition to antimalarial treatment, early in the course of admission (<24 hours) this could result in improvements in outcomes from severe malaria for the subgroups at greatest risk and during the period of greatest risk (the first day of hospitalisation). Sevuparin has been shown to be safe and well tolerated in adults with only some mild effects on activated partial thromboplastin time (APTT) at higher doses given over longer periods of time (3 days), which were transient and had no clinical consequences. We propose an initial investigation should be a Phase I trial which is designed to obtain data on safety, dosing, feasibility and potentially lactate clearance of sevuparin as an adjuvant therapy in severe malaria in children.

Our hypotheses

We hypothesize that sevuparin, a de-polymerised heparan sulphate mimetic, will improve microcirculatory flow by reversing and preventing parasite sequestration when given to children with severe malaria and will improve overall outcome.

Objectives

General objectives

The primary objective of this trial is to conduct a dose-finding study of intravenous sevuparin given in 3 doses over the

first 18 hours from enrolment (within 24h of hospital admission), defining toxicity events as any APTT >2.5 upper limit of normal (ULN) (grade 3 toxicity) 1 hour after each dose to identify the maximum tolerated dose (MTD). The initial dosage (1.5 mg/kg) and the *a priori* dose-toxicity curve are based upon the results of the adult trial (where a dose of 1.5 mg/kg was associated with minimal risk of toxicity) and experimental evidence of dose-dependent efficacy i.e. inhibition of merozoite invasion and reversal of cytoadherence of infected erythrocytes⁴². Almost all adults enrolled in this trial experienced grade 2 toxicity after one or more sevuparin doses, but APTT rapidly normalized, hence the choice of grade 3 toxicity to define the MTD in this dose-finding trial.

The primary endpoint for the future Phase II trial reflects the primary hypothesis that Sevuparin improves microcirculatory flow by reversing and preventing parasite sequestration. Data collected in the Phase I trial will also assess whether lactate clearance at 8-, 16- and 24 hours is a realistic and feasible primary endpoint for a subsequent Phase II trial.

Specific objectives

To identify the maximum tolerated dose (MTD) of intravenous sevuparin as an adjunctive therapy in children with severe malaria given as three infusions at 0, 8 and 16 hours using the Continual Reassessment Method (CRM) to adapt or inform subsequent doses for each child entering the trial, based on a toxicity event defined as any APTT >2.5 upper limit of normal (ULN) 1 hour after each dose, and updating the dose-toxicity model using the previous patients' APTT results. The secondary objective will be to assess whether lactate clearance at 8 hours is a realistic and feasible primary endpoint for a subsequent Phase II trial.

Methods

Study sites

The study will be conducted on the high dependency ward in Kilifi County Hospital, Kilifi Kenya and the paediatric ward at Nchelenge Hospital, Luapula Province, Zambia

Study design

A Phase I safety and dose finding trial

Study populations

Twenty children hospitalised with severe malaria

Inclusion criteria

1. Aged between 3 months and 12 years admitted to the paediatric wards within the last 24h
2. Current evidence of *P. falciparum* malaria (slide positive)
3. Clinical evidence of severe malaria: impaired consciousness: coma (inability to localize painful stimulus) or prostration (inability to sit unsupported for those above 6 months) or deep breathing
4. Lactate > 2 mmol/L
5. Guardian or parent willing and able to provide consent

Exclusion criteria

1. Clinical evidence or a history of a bleeding/coagulation disorder
2. A comorbidity which clinician believes has a significant risk of poor outcome e.g., malignancy, end-stage renal failure, major cardiac condition
3. Thrombocytopenia (platelet count <25 ×10⁹/L).

Sampling

Sample size determination

This is a Phase I trial designed to obtain data on safety, dosing, feasibility, and lactate clearance of sevuparin given as an adjuvant therapy in severe malaria. We aim to study 20 children since this will allow sufficient data on safety to be generated across a range of doses to identify the maximum tolerated dose (MTD) from a more informed model relating dose to toxicity events (denoted the 'dose-toxicity' curve) than that available *a priori* based on published data from adult studies. After each patient is enrolled, the dose-toxicity curve will be updated based on levels of APTT taken over three time points (1h post each infusion), defining a toxicity event as APTT >2.5xULN at any time point (grade 3 following the Common Toxicity Criteria (CTC)). This enables the MTD to be estimated more rapidly using the Continuous Reassessment Method (CRM)⁴⁹ once determined, subsequent participants will be allocated to this MTD to provide the most accurate estimate of future toxicity event rates until we reach the sample size of 20 children. However, the CRM method will continue to use information from all these children; for example, if a number of children receiving the originally identified MTD experience toxicity events, the dose would again be lowered, and future children would receive this lower dose.

Sampling procedures and methods. Children admitted to the paediatric wards of in Kilifi and Nchelenge Hospital children with suspected malaria and either coma or deep breathing (defining severe malaria for this Phase I study) will be screened by the paediatric triage/admission team for eligibility. Once eligibility is verified, the parents can be approached for consent and, if they agree to participate, they will receive their allocated treatment dosage. The blood tests taken at admission and during the trial include standard of care and research bloods (see [Table 2](#)). Admission and serial assessment of full blood count, admission point of care clinical chemistry including PH, blood cultures and repeated assessment of malaria parasitaemia are part of the standard clinical tests. Additional to this will be serial assessment of lactate, measurements of coagulation (by iSTAT (Kaolin ACT) and laboratory-based APTT) and samples will be stored in Kilifi for future pharmacokinetic (PK) tests, plasma HRP2 tests and malaria parasites(research). The reliability of Point of care ACT measurements (using the iSTAT) have previously assessed against a laboratory gold standard and have shown that the coefficients of variation of POC ACT and whole blood were between 2% and 3.6%, indicating that POC assessments are reliable and able to support on-site decision-making for patients in acute and intensive care⁶⁰.

Table 2. Clinical management schedule.

Procedure	Assessment Time										
	Adm	1h	2h	4h	8h	9h	17h	24h	Bi daily to discharge	Day 7	Day 28
Clinical assessment	X	X	X	X	X			X	X	X	X
ECG continuous to 24 hours (Kilifi)	X							X			
APTT and coagulation tests (ACT) (1.7ml)	X	X 1 hr post dose				X 1 hr post dose	X 1 hr post dose	X			
Microperfusion ^{&}	x					x	x				
Lactate (point of care)	X	X				X		X			
Standard clinical test non-research (FBC, POC chemistry Istat) [*]	X								X		X
Malaria slides	X					X		X	(36,48, 72 hrs)	X	X
Stored red cells & admission plasma ^{**}	X					X					X
PK sample		X				X					
Neuro-developmental assessment	X										X

[&] Kilifi Site only

^{*} Standard- non research clinical tests full blood count, clinical chemistry POC iSTAT (electrolytes, pH BUN) will be done at admission and at 24 hours and Day 7 (Full blood count only).

Other laboratory test: venous blood gases (including base excess) will be done at 0, 9 and 24 hours

Malaria slide and morphology will be done at 0, 9, 17, 24, 36, 48 hours (and 72 hours if in hospital); at follow up (Day 7 and 28)

^{**}For quantitative plasma HRP2 assessment, biomarkers and parasite morphology (Kilifi site only)

Management and outcome data will be collected (clinical parameters and recovery, developmental assessment, number of transfusions, use of drugs (specifically anticonvulsants, paracetamol, and antibiotics), date of discharge or in-hospital death. Contact and locator data will be recorded so that children can be followed at day 7 and day 28.

Consent process. Once eligibility has been confirmed, authorized trial staff will approach parents/guardians to invite their child to take part in the trial. An information sheet will be provided to the parent/guardian in their usual language. The sheet will be read aloud to those who are unable to read. The doctor/nurse will check that the information has been fully understood and parents/guardians will be encouraged to ask questions they may have about their child's participation.

Where possible, prospective written informed consent will be sought from parents/guardians by asking them to sign the Consent Form. If parents/guardians are unable to sign, a thumbprint will be taken in lieu of a signature. A copy of the Consent Form will be given to the parent/guardian, the original placed in the patient's medical notes, and a copy kept in the Investigator Site File.

If it is considered that the full consent process would significantly delay enrolment, and consequently be detrimental to the child's health, then emergency verbal assent, used in

previous trials⁶¹, will be sought from parents/guardians by the admitting medical team. Following verbal assent, written informed consent will be sought from the parent as soon as possible once the child's clinical condition has stabilized.

The participant information sheet, consent form and case report files can be found as *Extended data*⁶².

Trial treatments. We aim to study 20 children (See [Figure 1](#) Trial Flow). The trial will be open label with clinicians aware of study drug dosage. Laboratory staff performing APPT levels will be blind to drug dosage. All children will receive standard care including parenteral artesunate. Sevuparin will be given as three infusions at 0, 8 and 16 hours after enrolment. The initial participants (two 'cohorts' of 2 children each, i.e., 4 children in total) will receive a dose of 1.5 mg/kg/dose with the plan to escalate up to the next highest dose up to a maximum of 6.0 mg/kg/dose for subsequent children. In order to determine whether, and the rate of escalation, to move to a higher dosage for subsequent patients after the first 4 children we will use a design called the Continuous Reassessment Method (CRM). This starts with an *a priori* dose-toxicity curve, reflecting the probability of experiencing a toxicity event (here APTT>2.5xULN 1h after any of the three doses) to the dose received. In this method of dose finding, the dose-toxicity curve is re-fitted to the data after each child is enrolled, based on their observed dose and whether




Figure 1. Trial Flow.

they had a dose limiting toxicity event. After the first 4 children, each subsequent patient would be assigned the next highest dose, until the estimated risk of toxicity is just below or at the target toxicity level, designated as the maximum tolerated dose (MTD). The dose limiting toxicity (grade 3 APTT, >2.5xULN), *a priori* dose-toxicity curve and chosen target toxicity rate (15%) used in this trial have been based upon data shared by the investigators from the adult sevuparin studies in Thailand [36]. In particular, almost all adults enrolled in this trial experienced grade 2 toxicity after one or more sevuparin doses, but APTT rapidly normalized, hence the choice of grade 3 toxicity to define the MTD in this dose-finding trial. APTT 24h post-enrolment is a key secondary safety endpoint to confirm rapid normalization.

Any child with APTT>2.5xULN 1h after a dose of sevuparin will immediately discontinue trial treatment (and it would be counted as a toxicity event). They will continue to be

followed according to the trial schedule (on-study, off-study-drug), to confirm resolution of APTT and to record clinical outcomes.

Clinical assessments

Members of the clinical team and study team will all receive pre- and peri-trial training on the management of severe malaria. A manual of operations for the trial will be available for the study team, to anticipate and troubleshoot any potential issues. Vital signs will be monitored regularly (including temperature, heart rate, respiratory rate, blood pressure, oxygen saturation, conscious level). These will continue twice-daily after 24 hours until the child is discharged from HDU. All children will be managed on the HDU until conscious and able to take and retain oral fluids/food. During the period of sevuparin administration (0–24 hours) children in Kilifi, Kenya will have continuous electrocardiogram (ECG) monitoring for safety. However, it is notable that the trial

in Thai adults showed no signs of QT prolongation⁴². Once discharged from HDU children will be reviewed daily until discharge and followed up at day 7 and day 28. On admission and Day 28 children will be assessed by an adapted Kilifi Developmental Index to assess developmental status and clinically for neurodevelopmental sequelae (see Table 2). Non-compliance is limited by the intervention being administered by clinical teams during admission. Any child who develops APTT>2.5xULN (grade 3 toxicity) will not receive further doses of sevuparin but will continue to be followed up. Children lost to follow-up before day 28 will be traced for vital status (permission requested within consent) using locator data and multiple contact phone numbers recorded before discharge.

General clinical management

Children will initially receive parenteral antimalarial treatment (artesunate), followed by on day 3 (or when the child can safely take and retain oral feeds and fluids) an oral course of artemisinin combination therapy (ACT). All trial patients will receive intravenous antibiotics. Intravenous maintenance fluids will be given at a rate of 4ml/kg/hour until the child is able to drink and retain oral fluids. Antipyretics, anticonvulsants and treatment for hypoglycaemia and other treatments will be given as clinically required and will be administered according to nationally agreed protocols. Children with Hb <4 g/dl (or Hb <6 g/dl and respiratory distress) will be transfused with 20mls/kg of whole blood as soon as blood is available. In the absence of blood, standard care as per local treatment guidelines will be followed.

Protocol treatment discontinuation

An individual patient may stop treatment early or be stopped early for any of the following reasons:

- Unacceptable toxicity or adverse event
- Intercurrent illness that prevents further treatment
- Any change in the patient's condition that justifies the discontinuation of treatment in the clinician's opinion
- Withdrawal of consent for treatment by the patient or parent.

Participation in the trial is entirely voluntary, and parents, carers or older children may choose to discontinue the trial treatment at any time without penalty or loss of benefits to which they are otherwise entitled. Although not required to give a reason for discontinuing their trial treatment, a reasonable effort should be made to establish this reason while fully respecting the patient's rights.

Patients should remain in the trial for the purpose of follow-up wherever possible (unless the patient withdraws their consent for follow-up). If a patient withdraws from the trial, the medical data collected during their previous consented participation in the trial will be kept and used in analysis. This will also apply to parents/carers who withdraw from the trial after assent, that have not completed the deferred consent process. Consent for future use of stored samples already collected can

be refused when leaving the trial early (but this should be discouraged and should follow a discussion). If consent for future use of stored samples already collected is refused, then all such samples will be destroyed.

Trial products, storage and accountability

The drug product, sevuparin 150 mg/mL solution for intravenous (IV) infusion, is formulated in a 0.015M phosphate buffer at a pH of 7.0. It requires storage in a refrigerator at 2–8° and to be protected from light. The non-preserved sterile solution needs to be dispensed (5.4 mL) in a glass vial sealed with a rubber stopper and covered with a tear-off aluminium cap. The solution for administration will be prepared in a syringe and will be kept refrigerated and used within 24 hours. One vial will only be used for one subject. The drug product is produced in compliance with current Good Manufacturing Practice (GMP). The same material and compositions has been used in a clinical trial in children with sickle cell disease⁴³. From the product has been donated by MODUS Therapeutics, Sweden for use in this trial.

Sub studies

Assessments of the pharmacokinetics of Sevuparin

An aliquot of plasma from the samples taken during the trial will allow pharmacokinetic- pharmacodynamic (PKPD) modelling of the relationships between drug levels and longitudinal APTT and plasma lactate levels. The evaluation of the PK data will focus on the association between the sparsely sampled sevuparin concentrations and the APTT levels, plasma lactate levels and renal function. These assays will be contracted to Accelera (Nerviano (MI), Italy) since they have validated methodology for Sevuparin measurement and the data sent to MORU, Bangkok who will undertake the PK modelling at the end of the clinical study.

Assessment of microcirculation

The sublingual microcirculation will be assessed at the Kilifi site only using incident-dark field (IDF) imaging (CytoCam, Braedius Medical BV®). IDF orthogonal polarization spectroscopy imaging technology is a validated real-time visualization of the microcirculation using a 2ms pulsed green light emitted at a 530nm wavelength for optimal optical absorption by the haemoglobin in red blood cells, independent of oxygenation state. It is safe, non-invasive and can be performed rapidly at the patients' bedside. A sterilised disposable lens is used to prevent contact between the instrument and patient and therefore to prevent any transmission of infection. Two trained individuals will collect this data to limit inter-user variability. Images will be recorded from the proximal, mid, and distal portions in each half of the sublingual mucosa and averaged. Where possible the microcirculation will be assessed at time 0 (prior to sevuparin dose), at 8–9 hours (before and after infusion) and again at 17–18 hours (after final dose). The image acquisition and analysis used for assessment of the microcirculation will be in line with the 2018 consensus agreement. This will include a Capillary Network Analysis for vessel densities (total and perfused), the proportion of perfused vessel and the average perfusion speed indicator.

Additional laboratory investigation

At 1- and 8- hours and Day 28 plasma and red cell pellets will be used measure of the level Plasmodium falciparum Histidine Rich Protein (plasma). In addition the presence of rosetting and detailed microscopic examination of the infected red-cell morphology to stage the maturity of the parasite (Kilifi site only).

Trial outcome measures

Primary outcomes

APTT>2.5xULN 1h post any sevuparin dose (grade 3 following the CTC)

Secondary outcomes

Change in lactate from 0 to 8 hours

Presence of mature infected erythrocytes on the blood films at 8 and 24 hours

Parasite clearance time

(Change in sublingual microcirculation over time)

Safety endpoints

APTT 24h post enrolment (absolute level and grade)

Development of abnormalities of coagulation indices (prothrombin) (Grade 2 and above)

Neurological sequelae through day 28

Mortality through day 28

Serious adverse events through day 28

Grade 3/4 adverse events through day 28

APTT 24h post enrolment will be used as an assessment of normalization 8h after the final sevuparin dose. Both absolute levels and grade will be considered.

De-novo evidence of neurological sequelae will be ascertained using a modified Kilifi Developmental Index⁶³ assessed at admission (to identify pre-existing conditions) and follow up (which we have adapted to use for the other trials).

Serious adverse events will use the standardized definitions (see section 11 below). SAEs will be independently reviewed in real-time by the DMC. Adverse events will be graded following the Common Toxicity Criteria v5.0: (https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf).

SAEs and interim analyses

SAEs will be reviewed immediately by a designated physician (SAE reviewer) and reported to the appropriate ethics and regulatory committees within one week. The Chief Investigator will inform the Trial Steering Committee (TSC) and Data Monitoring Committee (DMC) for review on a regular basis (as deemed necessary). The DMC will review data

after the first 2 'cohorts' of 2 children each have been enrolled to the lowest dose, and then after each Dose Limiting Toxicity event. Professor Timothy Peto (Oxford) has agreed to be the Chairman is the DMC, other members will include an independent statistician and 2 pediatricians with relevant DMC or clinical trial experience. They will meet by regular teleconference. The continual reassessment method uses data from each enrolled participant to update the dose-toxicity curve and then suggests an escalation of dose to the largest dose with risk of estimated risk of toxicity below the target toxicity level if appropriate.

Trial monitoring The trial will be monitored by the Clinical Trial Facility in Kilifi which oversees standards and the quality of all trials conducted through the KWTP and through its monitoring systems and standard operating procedures are organised to ensure that all sites can be monitored with equal independence and rigor. All monitors will be appropriately qualified and trained. At each monitoring visit the monitors will:

- verify completeness of Trial Master File
- confirm adherence to protocol
- review eligibility verification and consent procedures
- look for missed clinical event reporting
- verify completeness, consistency and accuracy of data being entered on CRFs
- evaluate drug accountability
- provide additional training as needed

The monitors will require access to all patient medical records including, but not limited to, laboratory test results and prescriptions. The investigator (or delegated deputy) should work with the monitor to ensure that any problems detected are resolved.

Data management

All clinical and laboratory data will be recorded in the CRFs and stored with a unique serial number identifier. Data will be entered onto Open Clinica. All electronic data will be regularly backed up and backup copies stored both on and off site. Paper records will be archived in locked cabinets. These cabinets will have limited access with prior authorisation. All data will be partially- anonymized prior to presentation or publication of any results. Archive documents will be sent for long term storage (10 years) at an appropriate facility according to national policies.

Confidentiality

Participant's identification data will be required for the registration process. All clinical and laboratory data will be recorded

in the CRF and stored with a unique serial number identifier. Information will only be made available to those caring for the child and those directly involved with the study. Data will be entered onto Open Clinica (FDA approved, web-based application). All data will be regularly backed up and backup copies stored both on and off site. Paper records will be archived in locked cabinets. These cabinets will have limited access with prior authorisation. All data will be partially-anonymized prior to presentation or publication of any results. All clinical data will be held confidentially, and personal identifiers will be removed before analysis of the data and presentation of the results.

Data sharing

After completion of the study, requests for data access from researchers outside the study team will be considered by a subgroup of the Centre Scientific Committee (Data Governance Committee), and where indicated, requestors will be asked to develop scientific protocols for approval of secondary analyses. The potential to share data will be included in the participant Information and Consent Form.

Statistical analysis

Clinical data will be summarized using means and medians where appropriate for continuous data depending on the distribution. Primary and secondary endpoints will be described using means or medians or proportions. Analyses will follow intention-to-treat. As this is a Phase I trial no subgroup analyses are planned.

Ethics statement

Ethical approval has been obtained from Kenya Scientific and Ethics Review Unit (SERU), Nairobi Kenya on 25th February 2019 (protocol number GCMR-C/127/3744), Imperial College Research Ethics Committee (ICREC) on 13th July 2021 (protocol number 18IC4513) and National Health Research Ethics Board, Lusaka, Zambia on 24th July 2023 (protocol number NHREB001/24/07/2023). The trial was registered on the Pan Africa Clinical Trials PACTR number: 202007890194806 on 20/07/2020) and ISRCTN reference no 32271864 on 28/07/2021. These were updated on 18th August 2023.

Safety

The study will be performed in patients who may potentially benefit from the treatment. The risks of cannula insertion and blood drawing include pain, infection at the site of the cannula and thrombophlebitis. These will be minimised by careful technique according to a standard SOP, cannula site inspection and replacement or removal where necessary. No more than 1ml/kg of blood will be drawn for research at any one time. The trial will be recruiting patients with severe illness and likely a high mortality rate. At the start of the trial, the site will receive appropriate training on the use of Sevuparin and will have 2 dedicated clinicians. Sevuparin can lead to minimal and non-clinically relevant changes in APPT (grade II toxicity) In the Phase I dose escalation trial, sevuparin was found

to be safe and well-tolerated with minimal effects on APTT at doses of 1.5 mg/kg and 3mg/kg every six hours but a dose of 6.0 mg/kg led to higher APTT values⁴². The Data Monitoring Committee (DMC) therefore recommended that the study should continue to the Phase II with a dose of 3.0 mg/kg of sevuparin every 6h, given the potentially increased risk of adverse events at higher doses.

Risk will be minimised by the trial design/methods as described above under trial treatments. The escalation through the doses to find the maximum tolerated dose using the dose toxicity curve and data from children previously enrolled is carefully monitored by the DMC and Investigators.

Benefits

All patients will be closely monitored so that clinical deteriorations can be identified at the earliest opportunity and appropriate therapy initiated. Prior to the start, the dedicated study teams will undergo detailed training on general management of severe malaria and its complications and receive very detailed training on the use of sevuparin. We believe this will afford all children enrolled in the trial with a higher quality of care. All routine non-trial medications required by the hospital to treat the child will be made available. Hospital bills for participants will be covered by the study (covering the costs for standard treatment for severe malaria and related complications). The parents or guardians for the children will be asked to return for a follow up clinic visit at day 7 and day 28 and thus will be offered continuing care for intercurrent illness, including any investigations or blood tests that are clinically indicated.

Plans for dissemination of the study outcomes

Public engagement

Community engagement will be through regular meetings with the community involving community representatives and county Health teams. At these meetings, information and feedback will be given and received. Information arising from the study will be fed back through hospital-wide meetings. This is a Phase I trial of an emergency intervention where our engagement has been at a scientific rather than public/community level. If a larger platform trial arose from this study, we aim to develop a dedicated and informed engagement strategy as part of this future trial. In general, we plan to feed into existing community engagement mechanisms. We aim to build general community awareness of research processes at the local hospital, and support community representative inputs into decisions around research design, consent procedures, patient information and trial conduct.

National and international policymakers

When the results are available, we will provide a summary briefing highlighting the trial results and what then next steps will be. The current study will go some way towards addressing whether sevuparin is safe in severe malaria and inform the optimal dose to be investigated in a future trial. The results will be published in an open access journal.

Discussion

A novel drug candidate for adjunctive treatment of severe malaria, sevuparin, has been identified. This has been shown to block merozoite invasion, prevent cytoadherence and transiently de-sequester infected erythrocytes in adults with uncomplicated *P. falciparum* malaria. If given, in addition to antimalarial treatment, early in the course of admission (<24 hours) to children this could result in improvements in the outcome from severe malaria for the subgroups at greatest risk and during the period of greatest risk (first day of hospitalisation). Sevuparin has been shown to be safe and well tolerated with only some mild effects on APTT levels at higher doses given over a longer period of time (3 days), which is not clinically relevant to the time period of greatest risk (first day of hospitalization)⁴². In this Phase I trial dose-finding paediatric study, we aim to use 3 doses given at: admission (0 hours), and then 8 and 16 hours subsequently, and we will probable dose-limiting toxicity, APTT, 1 hour after each dose (to assess maximum toxicity). The normal ranges of APTT in children have been shown to be the same those in as adults⁶⁴ so this study will learn from and build upon what has already been published on sevuparin in adults with malaria. A large comprehensive study of coagulation abnormalities in African children with severe malaria, mild malaria and healthy controls demonstrated that there are no derangements in APTT in children with severe malaria compared to mild malaria and healthy controls⁵⁷, providing reassurance that the comparison of APTT levels with normal ranges in this study is clinically meaningful in terms of identifying a maximal tolerated dose (MTD).

The design of this dose finding study uses the Continual Reassessment Method (CRM). This adaptive dose-finding study design is increasingly embraced by clinical trialists⁶⁵ as a more efficient method for identifying an “optimal” dose using as small a number of participants as possible, in contrast with heuristic methods such as, for example, comparing three arbitrarily chosen doses. The CRM ‘learns’ (i.e., reassesses risk/toxicity) after each patient is entered into the trial and proposes a subsequent dose for the next child entered in a way that provides the most information about doses closest to the MTD. CRM has been shown to incur fewer toxicity events overall in identifying the MTD, and to estimate the MTD more accurately as compared to the standard Phase I dose escalation designs⁵⁹. In terms of safety, the study will be run using a ‘live’ Data Monitoring Committee (DMC) review of toxicity events. The DMC will review data after the first 2 ‘cohorts’ of 2 children each have been enrolled to the lowest dose (1.5 mg/kg/dose), and then after each Dose Limiting Toxicity (DLT) event.

The results of this Phase I trial will identify the final dosage selected for a subsequent Phase II that will include both efficacy and safety outcomes. The Phase II trial will be conducted by the SMAART consortium and plans to use

change in lactate at 8 hours as its primary endpoint; likely secondary endpoints include neurological sequelae, day-28 and day-180 mortality, length of initial hospitalisation, re-admission to hospital, grade 3/4 and serious adverse events. This Phase I trial will assess whether change in lactate at 8 hours is a realistic and feasible primary endpoint for a subsequent Phase II trial. These data will inform the need for a future Phase III trial with mortality as the primary endpoint.

Trial status

The trial opened for enrollment in Kenya on 21st Mar 2022. Batch expiry of sevuparin resulted in the following halts to the study: between 01st May 2022 and 19th May 2022; and 01st Nov 2022 to 09th Dec 2022 halt. Trial enrolment in Kenya was halted on 30th Jan 2023, following the proposed amendment. Enrollment is expected to start in Nchelenge in October 2023.

Protocol version changes

Version 1.0 was the original protocol submitted for ethical approval to Imperial College Ethics Committee (ICREC) version 1.2 was given full approval on 13th July 2021. The original protocol submitted to SERU was version 1.0 dated 18th May 2018, following comments from their reviewers the revisions were included and Version 1.2 dated 8th Feb 2019 was approved. Upon submission to the regulatory body (Pharmacy and Poisons Board), a couple of recommendations resulted in version 1.3 dated 2nd Sep 2020 was approved. ICREC granted a full approval of Version 1.3 on 17th Aug 2021. Version 2.0 and 2.1 included an additional site in Zambia and some changes to the blood collected to assay APPT. Version 2.0 and 2.1 received ICREC 's approval on 27th Mar 2023.

Data availability

Underlying data

No underlying data are associated with this article.

Extended data

Imperial College Research Data Repository: SEVUSMART extended data. <https://doi.org/10.14469/hpc/1327462>.

This project contains the following extended data:

- ICF SEVUSMART_v1.2 dated 28th Feb_2023_Clean English Copy.doc
- SEVUSMART Merged CRF's 16th May 2023.pdf

Reporting guidelines

Imperial College Research Data Repository: SPIRIT checklist for ‘SEVUparin as a potential Adjunctive Treatment in children with severe malaria : A Phase I trial Safety and Dose Finding Trial (SEVUSMAART)’. <https://doi.org/10.14469/hpc/1327558>.

Data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

Acknowledgements

Sponsor

Imperial College London is the main research Sponsor for this study. For further information regarding the sponsorship conditions, please contact the Head of Regulatory Compliance at:

Joint Research Office, Room 221b, Medical School Building, St Mary's Campus, Norfolk Place, London, W2 1PG. Telephone: +44 (0) 020 7594 1872.

Role of study sponsor and funders

The sponsor and funder played no role in study design and will play no role in data collection, trial management, analysis and interpretation of data and manuscript preparation the decision to submit the report for publication.

Trial Management Group

Kathryn Maitland, Emmanuel Oguda, Christabel Mogoka, Roisin Connon and Elizabeth C George

Safety Review Committee

Prof. Timothy Peto (Chair): University of Oxford; Prof Tim Peto;): London School of Hygiene and Tropical Medicine; and Dr Jane Crawley, University of Oxford.

References

1. Snow RW, Sartorius B, Kyalo D, *et al.*: **The prevalence of *Plasmodium falciparum* in sub-Saharan Africa since 1900.** *Nature.* 2017; **550**(7677): 515–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Noor AM, Kinyoki DK, Mundia CW, *et al.*: **The changing risk of *Plasmodium falciparum* malaria infection in Africa: 2000–10: a spatial and temporal analysis of transmission intensity.** *Lancet.* 2014; **383**(9930): 1739–47. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Alonso P, Noor AM: **The global fight against malaria is at crossroads.** *Lancet.* 2017; **390**(10112): 2532–4. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Organization WH: **World Malaria Report.** Geneva, 2017. [Reference Source](#)
5. Dondorp AM, Fanello CI, Hendriksen ICE, *et al.*: **Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.** *Lancet.* 2010; **376**(9753): 1647–57. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Maitland K: **Management of severe paediatric malaria in resource-limited settings.** *BMC Med.* 2015; **13**(1): 42. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Maitland K: **Severe Malaria in African children - the need for continuing investment.** *N Engl J Med.* 2016; **375**(25): 2416–7. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Okebe J, Eisenhut M: **Pre-referral rectal artesunate for severe malaria.** *Cochrane Database Syst Rev.* 2014; **2014**(5): CD009964. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. John CC, Kutamba E, Mugarura K, *et al.*: **Adjunctive therapy for cerebral malaria and other severe forms of *Plasmodium falciparum* malaria.** *Expert Rev Anti Infect Ther.* 2010; **8**(9): 997–1008. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. von Seidlein L, Olaosebikan R, Hendriksen ICE, *et al.*: **Predicting the clinical outcome of severe falciparum malaria in african children: findings from a large randomized trial.** *Clin Infect Dis.* 2012; **54**(8): 1080–90. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Ogetii GN, Akech S, Jemutai J, *et al.*: **Hypoglycaemia in severe malaria, clinical associations and relationship to quinine dosage.** *BMC Infect Dis.* 2010; **10**: 334. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Church J, Maitland K: **Invasive bacterial co-infection in African children with *Plasmodium falciparum* malaria: a systematic review.** *BMC Med.* 2014; **12**: 31. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Olupot-Olupot P, Engoru C, Uyoga S, *et al.*: **High frequency of blackwater fever among children presenting to hospital with severe febrile illnesses in Eastern Uganda.** *Clin Infect Dis.* 2017; **64**(7): 939–46. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Maitland K, Kiguli S, Opoka RO, *et al.*: **Mortality after fluid bolus in African children with severe infection.** *N Engl J Med.* 2011; **364**(26): 2483–95. [PubMed Abstract](#) | [Publisher Full Text](#)
15. Maitland K, Kiguli S, Olupot-Olupot P, *et al.*: **Immediate transfusion in African children with uncomplicated severe anemia.** *N Engl J Med.* 2019; **381**(5): 407–19. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Maitland K, Olupot-Olupot P, Kiguli S, *et al.*: **Transfusion volume for children with severe anemia in Africa.** *N Engl J Med.* 2019; **381**(5): 420–31. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Maitland K, Kiguli S, Olupot-Olupot P, *et al.*: **Randomised controlled trial of oxygen therapy and high-flow nasal therapy in African children with pneumonia.** *Intensive Care Med.* 2021; **47**(5): 566–76. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. White NJ, Turner GDH, Day NPJ, *et al.*: **Lethal malaria: Marchiafava and Bignami were right.** *J Infect Dis.* 2013; **208**(2): 192–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Kyes S, Horrocks P, Newbold C: **Antigenic variation at the infected red cell surface in malaria.** *Annu Rev Microbiol.* 2001; **55**: 673–707. [PubMed Abstract](#) | [Publisher Full Text](#)
20. Chen Q, Schlichtherle M, Wahlgren M: **Molecular aspects of severe malaria.** *Clin Microbiol Rev.* 2000; **13**(3): 439–50. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Dondorp AM, Kager PA, Vreeken J, *et al.*: **Abnormal blood flow and red blood cell deformability in severe malaria.** *Parasitol Today.* 2000; **16**(6): 228–32. [PubMed Abstract](#) | [Publisher Full Text](#)
22. Dondorp AM, Ince C, Charunwatthana P, *et al.*: **Direct *in vivo* assessment of microcirculatory dysfunction in severe falciparum malaria.** *J Infect Dis.* 2008; **197**(1): 79–84. [PubMed Abstract](#) | [Publisher Full Text](#)
23. Brown H, Turner G, Rogerson S, *et al.*: **Cytokine expression in the brain in human cerebral malaria.** *J Infect Dis.* 1999; **180**(5): 1742–6. [PubMed Abstract](#) | [Publisher Full Text](#)
24. Hanson J, Lam SWK, Mahanta KC, *et al.*: **Relative contributions of macrovascular and microvascular dysfunction to disease severity in falciparum malaria.** *J Infect Dis.* 2012; **206**(4): 571–9. [PubMed Abstract](#) | [Publisher Full Text](#)
25. Ishioka H, Ghose A, Charunwatthana P, *et al.*: **Sequestration and red cell deformability as determinants of hyperlactatemia in falciparum malaria.** *J Infect Dis.* 2016; **213**(5): 788–93. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Jeeyapant A, Kingston HW, Plewes K, *et al.*: **Defining surrogate endpoints for clinical trials in severe falciparum malaria.** *PLoS One.* 2017; **12**(1): e0169307. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Aramburo A, Todd J, George EC, *et al.*: **Lactate clearance as a prognostic marker of mortality in severely ill febrile children in East Africa.** *BMC Med.* 2018; **16**(1): 37. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Ponsford MJ, Medana IM, Prapansilp P, *et al.*: **Sequestration and microvascular congestion are associated with coma in human cerebral malaria.** *J Infect Dis.* 2012; **205**(4): 663–71. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Hendriksen ICE, White LJ, Veenemans J, *et al.*: **Defining falciparum-malaria-**

- attributable severe febrile illness in moderate-to-high transmission settings on the basis of plasma PfHRP2 concentration. *J Infect Dis.* 2013; 207(2): 351–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Angeletti D, Sandalova T, Wahlgren M, *et al.*: Binding of subdomains 1/2 of PfEMP1-DBL1a to heparan sulfate or heparin mediates *Plasmodium falciparum* rosetting. *PLoS One.* 2015; 10(3): e0118898.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 31. Barragan A, Fernandez V, Chen Q, *et al.*: The duffy-binding-like domain 1 of *Plasmodium falciparum* erythrocyte membrane protein 1 (PfEMP1) is a heparan sulfate ligand that requires 12 mers for binding. *Blood.* 2000; 95(11): 3594–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 32. Munir M, Husada T, Rampengan TH, *et al.*: Heparin in the treatment of cerebral malaria (a preliminary report). *Paediatr Indones.* 1976; 16(11–12): 489–95.
[PubMed Abstract](#)
 33. Munir M, Tjandra H, Rampengan TH, *et al.*: Heparin in the treatment of Cerebral Malaria. *Paediatr Indones.* 1980; 20(1–2): 47–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Hemmer CJ, Kern P, Holst FG, *et al.*: Neither heparin nor acetylsalicylic acid influence the clinical course in human *Plasmodium falciparum* malaria: a prospective randomized study. *Am J Trop Med Hyg.* 1991; 45(5): 608–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Reid HA, Sucharit P: Ancrod, heparin, and -aminocaproic acid in simian Knowlesi malaria. *Lancet.* 1972; 2(7787): 1110–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. Reid HA: Letter: Adjuvant treatment of severe falciparum malaria, intravascular coagulation, and heparin. *Lancet.* 1975; 1(7899): 167–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Carlson J, Ekre HP, Helmby H, *et al.*: Disruption of *Plasmodium falciparum* erythrocyte rosettes by standard heparin and heparin devoid of anticoagulant activity. *Am J Trop Med Hyg.* 1992; 46(5): 595–602.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Kulane A, Ekre HP, Perlmann P, *et al.*: Effect of different fractions of heparin on *Plasmodium falciparum* merozoite invasion of red blood cells *in vitro*. *Am J Trop Med Hyg.* 1992; 46(5): 589–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Leitgeb AM, Blomqvist K, Cho-Ngwa F, *et al.*: Low anticoagulant heparin disrupts *Plasmodium falciparum* rosettes in fresh clinical isolates. *Am J Trop Med Hyg.* 2011; 84(3): 390–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. Severe malaria. *Trop Med Int Health.* 2014; 19 Suppl 1: 7–131.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Saiwaew S, Sritabal J, Piaraksa N, *et al.*: Effects of sevuparin on rosette formation and cytoadherence of *Plasmodium falciparum* infected erythrocytes. *PLoS One.* 2017; 12(3): e0172718.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 42. Leitgeb AM, Charunwatthana P, Rueangveerayut R, *et al.*: Inhibition of merozoite invasion and transient de-sequestration by sevuparin in humans with *Plasmodium falciparum* malaria. *PLoS One.* 2017; 12(12): e0188754.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 43. Biemond BJ, Tombak A, Kilinc Y, *et al.*: Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Haematol.* 2021; 8(5): e334–e43.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Turner GD, Ly VC, Nguyen TH, *et al.*: Systemic endothelial activation occurs in both mild and severe malaria. Correlating dermal microvascular endothelial cell phenotype and soluble cell adhesion molecules with disease severity. *Am J Pathol.* 1998; 152(6): 1477–87.
[PubMed Abstract](#) | [Free Full Text](#)
 45. Boehme MW, Werle E, Kommerell B, *et al.*: Serum levels of adhesion molecules and thrombomodulin as indicators of vascular injury in severe *Plasmodium falciparum* malaria. *Clin Invest.* 1994; 72(8): 598–603.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. Hemmer CJ, Bierhaus A, von Riedesel J, *et al.*: Elevated thrombomodulin plasma levels as a result of endothelial involvement in *Plasmodium falciparum* malaria. *Thromb Haemost.* 1994; 72(3): 457–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. Gérardin P, Rogier C, Ka AS, *et al.*: Prognostic value of thrombocytopenia in African children with falciparum malaria. *Am J Trop Med Hyg.* 2002; 66(6): 686–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. Ladhani S, Lowe B, Cole AO, *et al.*: Changes in white blood cells and platelets in children with falciparum malaria: relationship to disease outcome. *Br J Haematol.* 2002; 119(3): 839–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Schmidt D, Gyr K: Malaria at the university hospital and the St.-Clara hospital, Basel, in the period of 1970-1979. *Bull Soc Pathol Exot Filiales.* 1983; 76(5): 486–92.
[PubMed Abstract](#)
 50. Pukrittayakamee S, White NJ, Clemens R, *et al.*: Activation of the coagulation cascade in falciparum malaria. *Trans R Soc Trop Med Hyg.* 1989; 83(6): 762–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 51. Clemens R, Pramoolsinsap C, Lorenz R, *et al.*: Activation of the coagulation cascade in severe falciparum malaria through the intrinsic pathway. *Br J Haematol.* 1994; 87(1): 100–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. Hemmer CJ, Kern P, Holst FG, *et al.*: Activation of the host response in human *Plasmodium falciparum* malaria: relation of parasitemia to tumor necrosis factor/cachectin, thrombin-antithrombin III, and protein C levels. *Am J Med.* 1991; 91(1): 37–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
 53. Marsh K, Forster D, Waruiru C, *et al.*: Indicators of life-threatening malaria in African children. *N Engl J Med.* 1995; 332(21): 1399–404.
[PubMed Abstract](#) | [Publisher Full Text](#)
 54. Reid HA, Nkrumah FK: Fibrin-degradation products in Cerebral Malaria. *Lancet.* 1972; 1(7744): 218–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
 55. Francischetti IMB, Seydel KB, Monteiro RQ, *et al.*: *Plasmodium falciparum*-infected erythrocytes induce Tissue Factor expression in Endothelial Cells and support the assembly of multimolecular coagulation complexes. *J Thromb Haemost.* 2007; 5(1): 155–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 56. Akingbola TS, Shokunbi WA, Olumese PE: Coagulation profile in Nigerian children with cerebral malaria. *Niger Postgrad Med J.* 2006; 13(3): 195–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. Moxon CA, Wassmer SC, Milner DA Jr, *et al.*: Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in Cerebral Malaria in African children. *Blood.* 2013; 122(5): 842–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 58. Maitland K: SPIRIT Checklist for 'SEVuparin as a potential Adjunctive Treatment in children with severe malaria: a Phase I trial safety and Dose Finding Trial (SEVUSMAART)'. Imperial College London Data Repository, 2023. <http://www.doi.org/10.14469/hpc/13275>
 59. Garrett-Mayer E: The Continual Reassessment Method for dose-finding studies: a tutorial. *Clin Trials.* 2006; 3(1): 57–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
 60. Niederdöckl J, Dempfle CE, Schönherr HR, *et al.*: Point-Of-Care PT and aPTT in patients with suspected deficiencies of coagulation factors. *Int J Lab Hematol.* 2016; 38(4): 426–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
 61. Maitland K, Molyneux S, Boga M, *et al.*: Use of deferred consent for severely ill children in a multi-centre phase III trial. *Trials.* 2011; 12: 90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 62. Maitland K: Sevuparin clinical trial: SEVUSMAAR. Imperial College London Data Repository, 2023. <http://www.doi.org/10.14469/hpc/13274>
 63. Abubakar A, Holding P, van Baar A, *et al.*: Monitoring psychomotor development in a resource-limited setting: an evaluation of the Kilifi Developmental Inventory. *Ann Trop Paediatr.* 2008; 28(3): 217–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 64. Andrew M, Vegh P, Johnston M, *et al.*: Maturation of the hemostatic system during childhood. *Blood.* 1992; 80(8): 1998–2005.
[PubMed Abstract](#) | [Publisher Full Text](#)
 65. Onar A, Kocak M, Boyett JM: Continual Reassessment Method vs. traditional empirically based design: modifications motivated by phase I trials in pediatric oncology by the Pediatric Brain Tumor Consortium. *J Biopharm Stat.* 2009; 19(3): 437–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:   

Version 2

Reviewer Report 29 August 2024

<https://doi.org/10.21956/wellcomeopenres.25245.r93306>

© 2024 Mmbando B. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Bruno Mmbando 

¹ Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania

² Tanga Research Centre, National Institute for Medical Research, Tanga, Tanzania

³ Public Health, Kampala International University - Dar es Salaam College, Dar es Salaam, Dar es Salaam, Tanzania

I have no further comments to make.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Epidemiology and Statistics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 29 August 2024

<https://doi.org/10.21956/wellcomeopenres.22271.r74237>

© 2024 J. Moehrle J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Joerg J. Moehrle 

¹ Medicines for Malaria Venture, Geneva, Geneva, Switzerland

² Medicines for Malaria Venture, Geneva, Geneva, Switzerland

Study proposal is a phase Ib study to assess the safety of sevuparin in children with severe malaria. The primary safety endpoint is the incidence of APTT > 2.5 LN 1h post infusion of sevuparin.

Secondary endpoints are change of lactate levels, presence of mature infected erythrocytes in peripheral blood, parasite clearance time and change in sublingual microcirculation.

It is a well-designed protocol to address the still high burden and mortality in children with severe malaria, even if these children receive the best available anti-parasitic drug, injectable artesunate.

My comments are:

1. Sevuparin is not a registered drug and I couldn't find any information on the availability of pre-clinical and clinical safety data, especially in children. The protocol also does not provide any information on the availability of preclinical data in juvenile animals. As the authors propose to proceed into children with severe malaria, a very vulnerable patient group, it would be important to ascertain, that the IMP has been tested in the relevant juvenile tox studies and found to be of no concern.
2. I have not found any assessment of potential interactions between sevuparin and artesunate (either on PK of both drugs and the antiparasitic effect of artesunate and DHA). It would be important for the review of the protocol, if either simulations, pre-clinical drug-drug interaction (DDI) studies or clinical DDI studies in healthy volunteers were available to exclude any risk for DDI, especially for a reduced exposure of artesunate and DHA when administered with sevuparin.
3. This protocol is based on previous studies in adults where "mild malaria" was treated with atovaquone/proguanil and sevuparin; and no negative effects were reported. I have several questions to this approach and its translation to support the proposed study.
 - a) What was the definition of mild malaria, what was the number of parasites/ul. Patient symptoms
 - b) Atovaquone/proguanil has quite different pharmacodynamic characteristics to injectable artesunate as this combination acts very slowly and even the onset of parasite elimination and symptom relief. has a lag of 24-48h.

For these reasons, I think that the rationale to move at this stage into vulnerable children is weak. The investigators should consider a pilot cohort where the safety, antimalarial effects and drug drug interactions are studied in patients with uncomplicated, but hyperparasitemic malaria and OR in an adaptive design study starting with patients >12 years and moderate severity, similar to the study "To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria" (ClinicalTrials.gov NCT04675931). If the outcome of this pilot cohort is confirming the tolerability, the beneficial effect of sevuparin on cytoadherence and the lack of significant drug drug interactions (PK as well as PD interactions), then inclusion of children with severe malaria and acidosis is justified.

I agree with proposed the two step process for obtaining consent for the study participation, however I would recommend that the abbreviated, oral information and consent should also be documented by signing (of fingerprint). Such an approach previously used in severe malaria trials

(Kremsner et al. J Infect Dis. 2012 Jan 15;205(2):312-9). Whenever possible assent of the pediatric patient should also be documented.

Minor comments:

The focus of the introduction is on the global burden of malaria and less on the burden of severe malaria and the high medical need to improve the standard of care to reduce mortality in children receiving adequate antimalarial treatment, ie injectable artesunate and therefore should be updated.

Although the mortality has not changed significantly from the numbers provided in the introduction based on the WHO Malaria Report 2016, the current numbers published by the WHO should be cited and referenced in the World Malaria Report 2023 (<https://iris.who.int/bitstream/handle/10665/374472/9789240086173-eng.pdf?sequence=1>)

It might also be informative to add to the introduction:

- What is the percentage of P falciparum infected children that develop severe malaria and especially acidosis
- Impact on K13 mutations on inj artesunate efficacy and increased risk of complications, even if parasite elimination half life remains at 6.5-7.5h, more sequestration?

Is the rationale for, and objectives of, the study clearly described?

Partly

Is the study design appropriate for the research question?

Partly

Are sufficient details of the methods provided to allow replication by others?

Partly

Are the datasets clearly presented in a useable and accessible format?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: malaria; drug development; translational research, PKPD modelling, epidemiology, pharmacology, infection biology; clinical trials;

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 05 April 2024

<https://doi.org/10.21956/wellcomeopenres.22271.r74240>

© 2024 Mmbando B. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Bruno Mmbando

¹ Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania

² Tanga Research Centre, National Institute for Medical Research, Tanga, Tanzania

³ Public Health, Kampala International University - Dar es Salaam College, Dar es Salaam, Dar es Salaam, Tanzania

⁴ Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania

⁵ Tanga Research Centre, National Institute for Medical Research, Tanga, Tanzania

⁶ Public Health, Kampala International University - Dar es Salaam College, Dar es Salaam, Dar es Salaam, Tanzania

This is phase I clinical trial aiming to determine the safety, feasibility and maximum tolerated dose of intravenous sevuparin as adjuvant therapy in children with severe malaria in children aged 3month to 12 years in Kenya and Zambia.

This is well written protocol with detailed literature and methodology to implement the trial.

However, the presentation could be improved if more details could be provided as follows:

1. Out of 20 participants how many will be recruited from Zambia/Kenya? Is this competitive?
2. Table 2: FBC will be done at 1hr, although in the Figure 1, this will be used for screening.
3. It is not how the cohorts of the two participants will be enrolled (parallel or sequentially?)
4. Figure 1: The trial flow is not straight forward to readers. e.g. in the box 3 - step 1 (2'cohorts of 2 children (n=4), this indicates that sevuparin infusion will be given for hours 0, 8 and 16 before decision whether it is safe or not. I would think this should only include hour 0, while the rest (hours 8 and 16) should appear in box 5 (a box with different dosages). Box 5 should not include hour 0.
5. Entries for the other cohorts besides the first 2 is not shown in the flow chart.

Other minor

1. Trial monitoring: This should be revised. Suggest to include a word "which" between Kilifi and oversees. Delete the word "are" between procedures and organised.
2. There is duplicate information between Data Management and Confidentiality. Please rearrange appropriately. See this semi-paragraph "All data will be regularly backed up and backup copies stored both on and off site. Paper records will be archived in locked cabinets. These cabinets will have limited access with prior authorisation. All data will be partially- anonymized prior to presentation or publication of any results"
3. Some abbreviations are missing, eg FBC and POC
4. Clinical assessment. Line no5 suggest to change word "monitoring" to "monitored"

Is the rationale for, and objectives of, the study clearly described?

Yes

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

No

Are the datasets clearly presented in a useable and accessible format?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Epidemiology and Statistics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 02 Aug 2024

Kathryn Maitland

We thank the review for a detailed appraisal of our trial protocol and particularly for identifying areas that needed correction. Here are our point by point responses to reviewer:

1. Out of 20 participants how many will be recruited from Zambia/Kenya? Is this competitive? **Response:** The recruitment at each site is not prescribed and when 20 are enrolled overall we will stop enrolment.
2. Table 2: FBC will be done at 1hr, although in the Figure 1, this will be used for screening. **Response:** Thank you. The table has been amended. FBC at admission.
3. It is not how the cohorts of the two participants will be enrolled (parallel or sequentially?) **Response:** Enrolled sequentially
4. Figure 1: The trial flow is not straight forward to readers. e.g. in the box 3 - step 1 (2 cohorts of 2 children (n=4), this indicates that sevuparin infusion will be given for hours 0, 8 and 16 before decision whether it is safe or not. I would think this should only include hour 0, while the rest (hours 8 and 16) should appear in box 5 (a box with different dosages). Box 5 should not include hour 0.
Response: The Trial flow demonstrates how the patient will be management. The top section details about whether there is or is not a Dose limiting toxicities will stop result in the patient not receiving additional doses The lower half details the Data Monitoring Committee decisions after reviewing the data and whether to recommend it is safe to escalate to the next dosage.
5. Entries for the other cohorts besides the first 2 is not shown in the flow chart.
Response: Please see the explanation given for the above. We aim to study initially 1.5 mg/kg/dose with the plan to escalate up to the next highest dose up to a maximum of 6.0 mg/kg/dose for subsequent children. In order to determine whether, and the rate of escalation, to move to a higher dosage for subsequent patients after the first 4 children we will use a design called the Continuous Reassessment Method (the flow chart should be

read alongside the details given under Trial treatments section).

Other minor

1. Trial monitoring: This should be revised. Suggest to include a word "which" between Kilifi and oversees. Delete the word "are" between procedures and organised.

Response: Thank you we have corrected this.

2. There is duplicate information between Data Management and Confidentiality. Please rearrange appropriately. See this semi-paragraph "All data will be regularly backed up and backup copies stored both on and off site. Paper records will be archived in locked cabinets. These cabinets will have limited access with prior authorisation. All data will be partially-anonymized prior to presentation or publication of any results".

Response: We have made some changes in the way this is reported. The final sentence have been retained "All electronic data will be regularly backed up with copies stored both on and off site. Paper records will be archived in locked cabinets which have limited access with prior authorisation".

3. Some abbreviations are missing, e.g. FBC and POC.

Response: Thank you we have added these.

4. Clinical assessment. Line no5 suggest to change word "monitoring" to "monitored".

Response: Thank you. Changed.

Competing Interests: No competing interests were disclosed.

Reviewer Report 02 January 2024

<https://doi.org/10.21956/wellcomeopenres.22271.r71475>

© 2024 Li M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Mei Li

¹ National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, China

² National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, China

It is the first time to know such interesting practice of publishing article. Only the STUDY PROTOCOL is available.

Basing on positive results in adult, this study aims to assess safety, dosing, feasibility of sevuparin as an adjuvant therapy in children with severe malaria complicated by lactic acidosis (> 2mmol/l). In my opinion, the rationale for, and objectives of, the study is clearly described, the study design appropriate for the research question, sufficient details of the methods provided to allow

replication by others, and the datasets are clearly presented in a useable and accessible format in the article.

However, there is an uncertain point. Is it the most suitable means to measure parasite biomass using histidine-rich protein2 (pfHRP2)? Is there evidence to support this usage? PfHRP2 might persist for a long time in successfully treated patients who had been infected by falciparum parasites, especially in children [Dalrymple U, Arambepola R, Gething PW, et al. [How long do rapid diagnostic tests remain positive after anti-malarial treatment? Malar J](#), 2018,17:228.].

Sevuparin, as a potential adjunctive treatment, will be used together with anti-malarial drugs. The change of parasite biomass or parasitemia is very important to following the patients' condition. So, parasite density is suggested to count in thin films or thick film ($\leq 40,000$ parasites/ μL blood) except of pfHRP2 test.

Is the rationale for, and objectives of, the study clearly described?

Yes

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: I mainly work on malaria diagnosis and control, and have taken part in the TES for anti-malaria drugs.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 02 Aug 2024

Kathryn Maitland

We thank the reviewer for a positive appraisal the the trial protocol. With regards to the question on measurement of parasite biomass using PfHRP2 there is a substantial literature on its superiority in estimating true biomass rather the parasitaemia. It was first described by the coauthors of this trial protocol. Of specific relevance to severe malaria, which results from extensive sequestration of parasitised erythrocytes, sequestered parasites secrete PfHRP2 into the plasma which is liberated at schizont rupture. The plasma concentration of PfHRP2 provide a better estimate for the patient's total parasite biomass, rather than peripheral parasitaemia (which assesses the less mature and pathogenic circulating stages (<https://doi.org/10.1371/journal.pmed.0020204>). In addition, PfHRP levels more accurately predict children who have true severe malaria from those with incidental parasitaemia, and is a better indicator of prognosis rather than parasitaemia (

<https://doi.org/10.1093/infdis/jis675>). We understand that low levels of HRP2 can persist even after clearance of malaria parasites. PfHRP in our study is being used to stratify risk at admission in children administered with severe and complicated disease.

Competing Interests: No competing interests were disclosed.
